Full Logo No Tagline Color
Donations
Donations
Lung cancer

New therapeutic approaches for lung cancer

SAKK researches targeted treatment methods for lung cancer. Find out how you can benefit as a patient.

Ongoing Studies

Recruitment completed

SAKK 16/18

Immunotherapy and radiotherapy in stage III non-small cell lung cancer

SAKK LuCa 2

Registry and study of EGFR-mutated NSCLC

salVage

Phase III randomized controlled trial comparing maintenance systemic therapy alone with systemic therapy plus local ablative treatment for patients with advanced stage IV non-small cell lung cancer

ETOP CHESS

A multicentre single arm phase II trial assessing the efficacy of radical immunotherapy and chemotherapy, stereotactic radiotherapy and surgery in patients with synchronous oligo-metastatic NSCLC

Study 22615
Recruitment completed

ACHILES

ACHILES Does immunotherapy improve survival in patients with small cell lung cancer with limited disease who have received chemotherapy and radiotherapy?

ETOP ADOPT

An international, multicentre, open-label randomised phase III trial to evaluate the benefit of adding adjuvant durvalumab after neoadjuvant chemotherapy plus durvalumab in patients with stage IIB-IIIB (N2) resectable NSCLC

ETOP RAISE

A single-arm phase II trial of the addition of niraparib to anti-PD-L1 antibody maintenance in patients with SLFN11-positive, extensive-disease small cell lung cancer. RAISE: Niraparib added to anti-PD-L1 antibody maintenance in SLFN11-positive, extensive-disease SCLC
Recruitment completed

SAKK 15/19

Study SAKK 15/19 Radiation of lung tumor and maintenance therapy with durvalumab following treatment with chemotherapy and durvalumab in patients with advanced small cell lung cancer

SAKK 19/17

Study SAKK 19/17 - Durvalumab in patients with PD-L1-positive advanced non-small cell lung cancer (NSCLC) and inadequate general condition - A multicenter single-arm phase II study.

Closed studies

SAKK 16/14

Neoadjuvant immunotherapy in locally advanced non-small cell lung cancer

Lung cancer project group

The Project Group Lung Cancer is a dynamic, multidisciplinary team that brings together medical oncologists, thoracic surgeons, radio-oncologists, and other specialists from across Switzerland. As one of the most active groups within the Swiss Cancer Institute, it fosters a vibrant exchange of ideas and expertise in the field of thoracic oncology.
Our research activities span the full spectrum of lung cancer, including non-small cell and small cell lung cancers, as well as rarer thoracic malignancies such as mesothelioma. The group is engaged in a wide range of research domains, including phase II and III clinical trials, registry and observational projects, translational research, and quality of life projects. We are open to new study proposals and continuously seek innovative approaches to improve patient outcomes. 
The Project Group Lung Cancer is committed to remaining at the forefront of clinical and translational research, adapting to the evolving scientific and regulatory environment while maintaining a strong focus on patient-centered care.